CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
07/26/07	$0.1288	0.00%	269
06/26/06	$0.1288	-	21,058
05/26/05	$0.000000	-100.00%	57
04/26/04	$0.1289	-0.08%	648
03/26/03	$0.1290	-	3,460

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 07:38:20 07/08/2026 pm IST			5-day change	1st Jan Change
0.1288 ^USD	0.00%		-4.59%	-84.85%

02/06	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
15/05	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	26.48L 22.9L 21.39L 19.62L 36.9L 25Cr 37.49L 2.51Cr 98.49L 13Cr 99.42L 97.25L 42Cr	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	2.45Cr 2.12Cr 1.98Cr 1.82Cr 3.41Cr 233.19Cr 3.47Cr 23Cr 9.11Cr 116.88Cr 9.2Cr 9Cr 386.4Cr	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

02/06	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
15/05	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/05	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/04	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
21/04	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03/03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03/03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

1 month	-2.20%
3 months	-7.34%
6 months	-86.07%
Current year	-84.85%

CASI Pharmaceuticals, Inc. Share Price Nasdaq

Stocks

CASI

KYG1933S1012

Pharmaceuticals

Valuation: CASI Pharmaceuticals, Inc.

Chart: CASI Pharmaceuticals, Inc.

Latest news : CASI Pharmaceuticals, Inc.

Press Releases: CASI Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: CASI Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 week	0.13	0.17
1 month	0.13	0.19
3 years	0.05	8.48
5 years	0.05	17.4
10 years	0.05	88.92

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CASI PHARMACEUTICALS, INC.	0.00%	-4.59%	-91.24%	-94.40%	26.48L
ELI LILLY AND COMPANY	-0.52%	+3.21%	+89.52%	+127.32%	1,05700Cr
JOHNSON & JOHNSON	+0.88%	+1.13%	+49.56%	+49.69%	62TCr
ABBVIE INC.	+0.89%	-1.95%	+24.23%	+64.44%	43TCr
ROCHE HOLDING AG	+0.71%	+3.87%	+49.07%	+37.85%	36TCr
NOVARTIS AG	+0.64%	-0.49%	+33.94%	+40.01%	30TCr
ASTRAZENECA PLC	+0.39%	-5.83%	+8.92%	+7.85%	25TCr
AMGEN INC.	+1.51%	+6.69%	+42.58%	+57.57%	22TCr
NOVO NORDISK A/S	+3.92%	-0.46%	-5.56%	-52.32%	21TCr
GILEAD SCIENCES, INC.	+1.80%	+2.30%	+11.56%	+66.35%	17TCr
Average	+1.14%	+0.87%	+21.26%	+30.44%	40.23TCr
Weighted average by Cap.	+0.66%	+1.22%	+48.72%	+64.63%

	2024	2025
Net sales	2.85Cr 2.47Cr 2.31Cr 2.11Cr 3.98Cr 271.59Cr 4.04Cr 27Cr 11Cr 136.13Cr 11Cr 10Cr 450.03Cr	2.07Cr 1.79Cr 1.67Cr 1.53Cr 2.89Cr 197.12Cr 2.93Cr 20Cr 7.7Cr 99Cr 7.78Cr 7.61Cr 326.63Cr
Net income	-3.93Cr -3.4Cr -3.17Cr -2.91Cr -5.47Cr -373.63Cr -5.56Cr -37Cr -15Cr -187.27Cr -15Cr -14Cr -619.11Cr	-4.81Cr -4.16Cr -3.88Cr -3.56Cr -6.7Cr -457.38Cr -6.8Cr -46Cr -18Cr -229.25Cr -18Cr -18Cr -757.88Cr
Net Debt	60.5L 52.33L 48.87L 44.83L 84.32L 58Cr 85.66L 5.73Cr 2.25Cr 29Cr 2.27Cr 2.22Cr 95Cr	2.19Cr 1.89Cr 1.77Cr 1.62Cr 3.05Cr 207.99Cr 3.09Cr 21Cr 8.13Cr 104.25Cr 8.21Cr 8.03Cr 344.64Cr